Vnitr Lek 2023, 69(2):E23-E25 | DOI: 10.36290/vnl.2023.025

Role of eplerenone in the threatment of cardiovascular diseases

Filip Málek
Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

Eplerenone is a selective mineralocorticoid receptor antagonist. Its approved for the therapy of patients with chronic heart failure with left ventricular systolic dysfunction and for the patients after myocardial infarction complicated by heart failure and left ventricular dysfunction. It´s also recommended for the therapy of primary hyperaldosteronism and the treatment of drug resistant hypertension.

Keywords: eplerenone, mineralocorticoid receptors, heart failure, hyperaldosteronism, resistant hypertension.

Accepted: March 29, 2023; Published: March 30, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Role of eplerenone in the threatment of cardiovascular diseases. Vnitr Lek. 2023;69(2):E23-25. doi: 10.36290/vnl.2023.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Málek F, ©paček R. Blokáda receptoru aldosteronu v terapii chronického srdečního selhání. Cor Vasa. 2002,44:32-36.
    2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131. Go to original source...
    3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. Go to original source... Go to PubMed...
    4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction N Engl J Med. 2003;348:1309-21. Go to original source... Go to PubMed...
    5. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. Go to original source... Go to PubMed...
    6. Mairgani G, Mále V, Málek F. The importance of a higher dose of a mineralocorticoid receptor antagonist in reducing risk of reccurent hospitalization in a patient with advanced chronic heart failure - a case report. Cor Vasa 2018;60:e527-530. Go to original source...
    7. Capuano A, Scavone C, Vitale C, et al. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int J Cardiol. 2015,200:15-19. Go to original source... Go to PubMed...
    8. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze. Doporučení České společnosti pro hypertenzi. Hypertenze α kardiovaskulární prevence Suppl. 2022;12(2):1-25.
    9. SPC Eplerenon. Available from: file:///C:/Users/11366/Downloads/eplerenon‑sandoz‑spc%20(1).pdf.Riziko úmrtí-15 %, p = 0,008Riziko úmrtí a hospitalizace z KV příčin-13 %, p = 0,002Riziko náhlé srdeční smrti-21 %, p = 0,03

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.